Novo Nordisk to acquire Prothena’s ATTR amyloidosis programme for $1.2bn

Novo Nordisk to acquire Prothena’s ATTR amyloidosis programme for $1.2bn. Credit: Capri23auto from Pixabay.



  • Novo